Medicare Ratings Showdown: CMS Fights Back Against Court Ruling
In a significant development for Medicare Advantage plans, the Centers for Medicare & Medicaid Services (CMS) has announced its intention to appeal a November 2024 ruling, setting the stage for a legal battle in the Fifth Circuit Court of Appeals.
The latest CMS data reveals a notable shift in the landscape of Medicare Advantage plans with prescription drug coverage. For the 2025 plan year, approximately 40% of plans achieved a four-star rating or higher—a marked decrease from the current year's performance. Among the notable performers, UnitedHealth secured a respectable four-star rating.
This decline in star ratings could have substantial implications for healthcare providers and beneficiaries alike. The star rating system, which evaluates plans based on quality, customer service, and patient experience, plays a crucial role in helping Medicare recipients make informed healthcare choices.
The CMS's decision to appeal the recent ruling, coupled with the changing star ratings, signals potential significant changes in the Medicare Advantage market. Healthcare industry observers and stakeholders will be closely watching the developments as they unfold.